The stock price of Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) has dropped by -5.23 compared to previous close of 0.16. Despite this, the company has seen a fall of -16.98% in its stock price over the last five trading days. InvestorPlace reported 2024-04-09 that It is not a bad idea to hunt for biotech stocks to sell. Such stocks have earned a bad reputation among investors, and for good reason.
Is It Worth Investing in Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) Right Now?
Moreover, the 36-month beta value for TNXP is 2.22. Analysts have varying opinions on the stock, with 3 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TNXP is 84.49M and currently, short sellers hold a 1.48% of that float. On April 15, 2024, TNXP’s average trading volume was 2.05M shares.
TNXP’s Market Performance
The stock of Tonix Pharmaceuticals Holding Corp (TNXP) has seen a -16.98% decrease in the past week, with a -53.66% drop in the past month, and a -48.01% fall in the past quarter. The volatility ratio for the week is 8.92%, and the volatility levels for the past 30 days are at 14.00% for TNXP. The simple moving average for the past 20 days is -38.94% for TNXP’s stock, with a -76.43% simple moving average for the past 200 days.
Analysts’ Opinion of TNXP
ROTH Capital, on the other hand, stated in their research note that they expect to see TNXP reach a price target of $4. The rating they have provided for TNXP stocks is “Buy” according to the report published on April 18th, 2019.
ROTH Capital gave a rating of “Buy” to TNXP, setting the target price at $6 in the report published on August 18th of the previous year.
TNXP Trading at -50.79% from the 50-Day Moving Average
After a stumble in the market that brought TNXP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -95.68% of loss for the given period.
Volatility was left at 14.00%, however, over the last 30 days, the volatility rate increased by 8.92%, as shares sank -50.93% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -54.22% lower at present.
During the last 5 trading sessions, TNXP fell by -15.09%, which changed the moving average for the period of 200-days by -89.43% in comparison to the 20-day moving average, which settled at $0.2440. In addition, Tonix Pharmaceuticals Holding Corp saw -61.79% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for TNXP
Current profitability levels for the company are sitting at:
- -2.84 for the present operating margin
- 0.13 for the gross margin
The net margin for Tonix Pharmaceuticals Holding Corp stands at -2.76. The total capital return value is set at -0.87. Equity return is now at value -74.61, with -61.38 for asset returns.
Based on Tonix Pharmaceuticals Holding Corp (TNXP), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -11.04. The debt to equity ratio resting at 0.09. The interest coverage ratio of the stock is 66.13.
Currently, EBITDA for the company is -114.09 million with net debt to EBITDA at 0.13. When we switch over and look at the enterprise to sales, we see a ratio of -0.05. The receivables turnover for the company is 9.08for trailing twelve months and the total asset turnover is 0.27. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.53.
Conclusion
To wrap up, the performance of Tonix Pharmaceuticals Holding Corp (TNXP) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
